SCHEMBL1259232

SCHEMBL1259232

Cc1cccc(C)c1-n1cccc(C(=O)O)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
HPGD P15428 3/20 0.49
KDM4E B2RXH2 3/20 0.49
HSD17B10 Q99714 3/20 0.49
MYC P01106 3/20 0.45
POLB P06746 3/20 0.42
KMT2A Q03164 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
APEX1 P27695 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 2/20 0.41
AKR1C3 P42330 2/20 0.41
AKR1B10 O60218 1/20 0.41
TRPA1 O75762 1/20 0.41
ABCB11 O95342 1/20 0.41
DHFR P00374 1/20 0.41
LMNA P02545 1/20 0.41
MPO P05164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1260115 0.82 POLB (0.53) ALDH1A1HPGDKDM4EHSD17B10MYC
SCHEMBL26601369 0.77 AKR1C3 (0.49) ALDH1A1HPGDKDM4EHSD17B10POLB
SCHEMBL4628972 0.77 POLB (0.63) ALDH1A1HPGDKDM4EHSD17B10MYC
SCHEMBL5759739 0.76 NOTUM (0.52) ALDH1A1HPGDKDM4EPOLBKMT2A
SCHEMBL1137068 0.75 KDM4E (0.54) ALDH1A1HPGDKDM4EHSD17B10POLB
SCHEMBL4313192 0.75 ALDH1A1 (0.42) ALDH1A1KDM4EHSD17B10POLBKMT2A
SCHEMBL31339753 0.74 HTT (0.42) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL21186942 0.74 HTT (0.42) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL5759824 0.73 MYC (0.41) ALDH1A1HPGDKDM4EHSD17B10MYC
SCHEMBL1260315 0.73 P2RX7 (0.42) ALDH1A1KDM4EPOLBKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
WO-2009136663-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF ABL1, MAP4K2, MAP3K20 ALDH1A1 2255/4885HPGD 2136/4885KDM4E 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.